HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adenovirus-encoded hammerhead ribozyme to PDGF A-chain mRNA inhibits neointima formation after arterial injury.

Abstract
To develop a strategy for gene therapy of restenosis following coronary angioplasty, we examined the effects of a recombinant adenovirus vector encoding a hammerhead ribozyme specific for rat platelet-derived growth factor (PDGF) A-chain mRNA (Ad. Ribozyme) and a control recombinant adenovirus vector encoding the Escherichia coli LacZ gene (Ad.LacZ) on neointima formation in rat carotid artery after balloon injury. Ad. Ribozyme (10(8) PFU/ml) markedly reduced the increased expression of PDGF A-chain mRNA and protein. Ad. Ribozyme significantly decreased the intima/media ratio (68%) of the injured artery, whereas Ad.LacZ had no effect on the intima/media ratio. Most carotid arteries developed thrombi by 14 days after balloon injury, whereas Ad. Ribozyme completely inhibited thrombus formation. Expression of thromboxane A2 (TXA2) receptor mRNA was significantly increased after balloon injury. Ad. Ribozyme significantly decreased the levels of TXA2 receptor. Expression of prostaglandin I2 (PGI2) synthase mRNA was significantly decreased after balloon injury. Ad. Ribozyme significantly increased levels of PGI2 synthase mRNA after balloon injury. The observation that adenovirus-encoded ribozyme to PDGF A-chain inhibits neointima formation may serve as a novel strategy to prevent restenosis after coronary angioplasty. Inhibition of growth factors by genetic approaches may yield new insights into the mechanisms underlying responses to vascular injury and lead to new therapeutic applications.
AuthorsZhi-Hong Lin, Noboru Fukuda, Ryo Suzuki, Hiroto Takagi, Yukihiro Ikeda, Satoshi Saito, Koichi Matsumoto, Katsuo Kanmatsuse, Hideo Mugishima
JournalJournal of vascular research (J Vasc Res) 2004 Jul-Aug Vol. 41 Issue 4 Pg. 305-13 ISSN: 1018-1172 [Print] Switzerland
PMID15192266 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Platelet-Derived Growth Factor
  • RNA, Catalytic
  • RNA, Messenger
  • Receptors, Thromboxane A2, Prostaglandin H2
  • hammerhead ribozyme
  • platelet-derived growth factor A
  • Epoprostenol
Topics
  • Adenoviridae (genetics)
  • Animals
  • Carotid Arteries (drug effects, metabolism)
  • Carotid Artery Diseases (prevention & control)
  • Carotid Artery Injuries (complications)
  • Catheterization
  • Epoprostenol (genetics)
  • Gene Transfer Techniques
  • Genetic Vectors
  • Male
  • Neovascularization, Pathologic (prevention & control)
  • Platelet-Derived Growth Factor (antagonists & inhibitors, genetics)
  • RNA, Catalytic (genetics, pharmacology)
  • RNA, Messenger (antagonists & inhibitors, drug effects)
  • Rats
  • Rats, Wistar
  • Receptors, Thromboxane A2, Prostaglandin H2 (genetics)
  • Thrombosis (prevention & control)
  • Tunica Intima (drug effects)
  • Wounds, Nonpenetrating (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: